Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.48
IRWD's Cash to Debt is ranked higher than
70% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IRWD: 1.48 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.48

Equity to Asset 0.31
IRWD's Equity to Asset is ranked higher than
51% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IRWD: 0.31 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.74
Current: 0.31

-1.86
0.74
F-Score: 3
Z-Score: 0.70
M-Score: -0.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -421.68
IRWD's Operating margin (%) is ranked lower than
52% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. IRWD: -421.68 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -421.68

-1101.36
-48.43
Net-margin (%) -470.01
IRWD's Net-margin (%) is ranked lower than
52% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. IRWD: -470.01 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -470.01

-1192.31
-48.34
ROE (%) -181.66
IRWD's ROE (%) is ranked lower than
54% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. IRWD: -181.66 )
IRWD' s 10-Year ROE (%) Range
Min: -299.34   Max: -48.14
Current: -181.66

-299.34
-48.14
ROA (%) -58.58
IRWD's ROA (%) is ranked lower than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. IRWD: -58.58 )
IRWD' s 10-Year ROA (%) Range
Min: -107.22   Max: -22.85
Current: -58.58

-107.22
-22.85
ROC (Joel Greenblatt) (%) -507.78
IRWD's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. IRWD: -507.78 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.79   Max: -194.55
Current: -507.78

-672.79
-194.55
Revenue Growth (3Y)(%) -25.80
IRWD's Revenue Growth (3Y)(%) is ranked higher than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. IRWD: -25.80 )
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -25.8
Current: -25.8

EBITDA Growth (3Y)(%) 52.00
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. IRWD: 52.00 )
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 52
Current: 52

0
52
EPS Growth (3Y)(%) 54.30
IRWD's EPS Growth (3Y)(%) is ranked higher than
95% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. IRWD: 54.30 )
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 54.3
Current: 54.3

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IRWD Guru Trades in Q4 2013

Vanguard Health Care Fund 3,364,198 sh (+0.48%)
Steven Cohen Sold Out
» More
Q1 2014

IRWD Guru Trades in Q1 2014

John Burbank 16,207 sh (New)
Vanguard Health Care Fund 3,901,498 sh (+15.97%)
» More
Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

IRWD Guru Trades in Q3 2014

Steven Cohen 1,292,500 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$12.17 - $15.69 $ 14.799%0
Joel Greenblatt 2014-06-30 New Buy0.01%$9.71 - $15.5 $ 14.7914%27789
John Burbank 2014-06-30 Sold Out 0.01%$9.71 - $15.5 $ 14.7914%0
John Burbank 2014-03-31 New Buy0.01%$11.43 - $15.35 $ 14.7910%16207
Vanguard Health Care Fund 2013-06-30 Add 48.42%0.04%$9.93 - $18.17 $ 14.792%3238136
Lee Ainslie 2013-03-31 Sold Out 0.34%$11.08 - $18.85 $ 14.790%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.21
IRWD's P/B is ranked higher than
50% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. IRWD: 19.21 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 19.21

5.46
46.91
P/S 46.22
IRWD's P/S is ranked higher than
54% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. IRWD: 46.22 )
IRWD' s 10-Year P/S Range
Min: 2.6   Max: 75.05
Current: 46.22

2.6
75.05
EV-to-EBIT -10.81
IRWD's EV-to-EBIT is ranked lower than
56% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. IRWD: -10.81 )
IRWD' s 10-Year EV-to-EBIT Range
Min: -40   Max: -4.2
Current: -10.81

-40
-4.2
Current Ratio 5.63
IRWD's Current Ratio is ranked higher than
88% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. IRWD: 5.63 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 9.64
Current: 5.63

2.33
9.64
Quick Ratio 5.38
IRWD's Quick Ratio is ranked higher than
89% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. IRWD: 5.38 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 9.04
Current: 5.38

2.33
9.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 77.84
IRWD's Price/Net Cash is ranked higher than
84% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IRWD: 77.84 )
IRWD' s 10-Year Price/Net Cash Range
Min: 8.78   Max: 1184
Current: 77.84

8.78
1184
Price/Net Current Asset Value 61.62
IRWD's Price/Net Current Asset Value is ranked higher than
78% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IRWD: 61.62 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 8.48   Max: 131.56
Current: 61.62

8.48
131.56
Price/Tangible Book 19.21
IRWD's Price/Tangible Book is ranked higher than
56% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. IRWD: 19.21 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.99   Max: 36.28
Current: 19.21

5.99
36.28
Price/Median PS Value 2.23
IRWD's Price/Median PS Value is ranked higher than
58% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. IRWD: 2.23 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 3.12
Current: 2.23

0.15
3.12
Earnings Yield (Greenblatt) -9.30
IRWD's Earnings Yield (Greenblatt) is ranked higher than
52% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. IRWD: -9.30 )
IRWD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -9.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa Dec 10 2014
Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis Dec 09 2014
Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis Dec 09 2014
Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide... Nov 21 2014
Synergy Pharmaceuticals Drug Fares Well in Phase II Study Nov 20 2014
Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide... Nov 20 2014
IRONWOOD PHARMACEUTICALS INC Financials Nov 14 2014
10-Q for Ironwood Pharmaceuticals, Inc. Nov 07 2014
Ironwood Pharmaceuticals (IRWD) Stock Downgraded Today at Cantor Fitzgerald Nov 06 2014
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected Nov 06 2014
[video]Analysts' Actions: American Electric, Cornerstone OnDemand, CST Brands Nov 06 2014
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 05 2014
Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference Nov 05 2014
Ironwood beats 3Q profit forecasts Nov 04 2014
Ironwood beats 3Q profit forecasts Nov 04 2014
Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with... Nov 04 2014
Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update Nov 04 2014
Ironwood Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Nov 04 2014
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2014
Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with... Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK